Adult: In combination with lenalidomide and dexamethasone in patient who have received at least one prior treatment: 4 mg once weekly given on days 1, 8, and 15 of a 28-day treatment cycle, continue until disease progression or unacceptable toxicity. Dose reduction, dosing interruption, or discontinuation may be required according to individual safety and tolerability (refer to detailed product guideline).
Severe CrCl <30mL/min or ESRD requiring dialysis: Initially, 3 mg.
Moderate or severe: Initially, 3 mg.
Cap: Should be taken on an empty stomach. Take at least 1 hr before or 2 hr after food. Swallow whole w/ water, do not crush/chew/open.
Severe renal and moderate or severe hepatic impairment. Pregnancy.
This drug may cause dizziness, if affected, do not drive or operate machinery.
Monitor platelet counts monthly during treatment, and more frequently during the initial 3 cycles; CBC; renal and LFT. Monitor for gastrointestinal and dermatologic toxicity; signs and symptoms of neuropathy and peripheral oedema.
Description: Ixazomib is a proteasome inhibitor which reversibly binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome leading to activation of signaling cascades, cell-cycle arrest and apoptosis of tumour cells. Pharmacokinetics: Absorption: Bioavailability: 58%. Food, particularly high fat meal, decreases rate and extent of absorption. Time to peak plasma concentration: Approx 1 hour. Distribution: Plasma protein binding: 99%. Metabolism: Metabolised in the liver by CYP enzymes and non-CYP proteins. Excretion: Urine (62%, <3.5% as unchanged drug); faeces (22%). Terminal half-life: 9.5 days.
Store below 30°C. Protect from moisture.
This is a cytotoxic drug. Any unused portions should be disposed of in accordance with local requirements.
L01XG03 - ixazomib ; Belongs to the class of proteasome inhibitors. Used in the treatment of cancer.
Anon. Ixazomib. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 05/03/2019.Buckingham R (ed). Ixazomib. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/03/2019.Ixazomib. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com/. Accessed 01/03/2019.Joint Formulary Committee. Ixazomib. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/03/2019.Ninlaro Capsules (Millennium Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 01/03/2019.